Investor Relations

AgeneBio is dedicated to developing treatments designed to address hippocampal overactivity.

Investment Thesis

Novel Pipeline for Neurological and Psychiatric Diseases Addressing Significant Unmet Medical Needs

Extensive Phase 3 expertise in Alzheimer’s disease (AD) among R&D leadership team
Science recognized as novel and promising by AD experts
Phase 2b/Phase 3 program is in process

Recent News

AgeneBio Announces Completion of Patient Enrollment in Phase 2B Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease

Founder & CEO Dr. Michela Gallagher Featured in Alzheimer’s Drug Discovery Foundation Video

AgeneBio Announces Additional Funding to Advance Novel GABA-A Therapeutic Program to Address Alzheimer’s and Other CNS Conditions

T.J. Oshie and Dr. Michela Gallagher Honored at Ninth Annual Great Ladies Luncheon

AgeneBio Believes a Switch in Research Strategy Can Make Alzheimer’s Preventable

AgeneBio Announces First Patient Enrollment in the Phase 3 Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease

AgeneBio Announces Two NIH Grant Awards to Advance its Therapeutic Pipeline to Combat Progression of Alzheimer’s Disease

More news releases

AgeneBio in the news

Email Alerts

Sign up for email alerts here.

Investor Contact

Michela Gallagher
investorrelations@agenebio.com

Media Contact

press@agenebio.com
Hilary Lefebvre | Acadia Co. | 212.300.4929